The systemic treatment of uterine leiomyosarcomas A systematic review. No news is good news?

Background: Uterine leiomyosarcomas are rare malignant mesenchymal tumors. The systemic treatment of these tumors includes chemotherapy and radiotherapy. However, there are still a lot of unanswered questions regarding the ideal therapeutic approach. Methods: We have conducted a systematic review of the treatment strategies of uterine leiomyosarcomas for the last ten years. Results: Adjuvant chemotherapy is still a matter of dilemma. Doxorubicin based chemotherapy or the combination of Gemcitabine-Docetaxel are the regimens of choice for the first line setting. Beyond the first line, there are several options;, including chemotherapy, targeted therapy, and recently efforts of introducing immunotherapy to the therapeutic armamentarium of clinicians treating uterine leiomyosarcomas. Conclusions: Despite the efforts of the clinicians dealing with uterine leiomyosarcomas, the optimal therapeutic algorithm is yet to be described.

Automated summary

Uterine leiomyosarcomas are rare malignant mesenchymal tumors, and there are various treatment options including chemotherapy, targeted therapy, and immunotherapy. However, the optimal therapeutic algorithm has yet to be determined despite efforts by clinicians.